Literature DB >> 12570938

Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.

Masahiro Mohri1, Hiroaki Shimokawa, Yoji Hirakawa, Akihiro Masumoto, Akira Takeshita.   

Abstract

OBJECTIVES: We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm.
BACKGROUND: Effective treatment of patients with angina who have normal coronary arteriograms (microvascular angina) has not yet been established. Rho-kinase-mediated calcium sensitization of the myosin light chain in smooth muscle cells has been implicated as substantially contributing to vascular hyperconstriction.
METHODS: We studied consecutive 18 patients with angina and normal epicardial coronaries in whom intracoronary acetylcholine (ACh) induced myocardial ischemia (ischemic electrocardiographic changes, myocardial lactate production, or both) without angiographically demonstrable epicardial coronary vasospasm. All patients underwent a second ACh challenge test after pretreatment with either saline (n = 5) or fasudil (4.5 mg intracoronarily, n = 13).
RESULTS: Myocardial ischemia was reproducibly induced by ACh in the saline group. In contrast, 11 of the 13 patients pretreated with fasudil had no evidence of myocardial ischemia during the second infusion of ACh (p < 0.01). The lactate extraction ratio (median value [interquartile range]) during ACh infusion was improved by fasudil pretreatment, from -0.16 (-0.25 to 0.04) to 0.09 (0.05 to 0.18) (p = 0.0125).
CONCLUSIONS: Fasudil ameliorated myocardial ischemia in patients who were most likely having coronary microvascular spasm. The inhibition of Rho-kinase may be a novel therapeutic strategy for this group of patients with microvascular angina.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12570938     DOI: 10.1016/s0735-1097(02)02632-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  41 in total

Review 1.  Angina pectoris and normal coronary arteries: cardiac syndrome X.

Authors:  Filippo Crea; Gaetano A Lanza
Journal:  Heart       Date:  2004-04       Impact factor: 5.994

2.  Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.

Authors:  Hiroshi Fujita; Yoshihiro Fukumoto; Kenya Saji; Koichiro Sugimura; Jun Demachi; Jun Nawata; Hiroaki Shimokawa
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 3.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

4.  A novel cardioprotective mechanism of exogenous nitric oxide: inhibition of Rho-associated kinase activity.

Authors:  Atsushi Tanaka; Koichi Node
Journal:  Hypertens Res       Date:  2015-04-23       Impact factor: 3.872

Review 5.  Rho kinase inhibition in diabetic kidney disease.

Authors:  Radko Komers
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

6.  Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its activity and expression.

Authors:  Yi-Chu Liao; Ping-Yen Liu; Hsiu-Fen Lin; Wen-Yi Lin; James K Liao; Suh-Hang H Juo
Journal:  J Mol Cell Cardiol       Date:  2014-12-03       Impact factor: 5.000

7.  Quantitative and systems pharmacology 4. Network-based analysis of drug pleiotropy on coronary artery disease.

Authors:  Jiansong Fang; Chuipu Cai; Yanting Chai; Jingwei Zhou; Yujie Huang; Li Gao; Qi Wang; Feixiong Cheng
Journal:  Eur J Med Chem       Date:  2018-10-15       Impact factor: 6.514

Review 8.  Applications for ROCK kinase inhibition.

Authors:  Michael F Olson
Journal:  Curr Opin Cell Biol       Date:  2008-02-20       Impact factor: 8.382

Review 9.  Treatment of refractory angina in patients not suitable for revascularization.

Authors:  Timothy D Henry; Daniel Satran; E Marc Jolicoeur
Journal:  Nat Rev Cardiol       Date:  2013-12-24       Impact factor: 32.419

Review 10.  RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.

Authors:  Scott A Barman; Shu Zhu; Richard E White
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.